Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edralbrutinib (SHR1459) in Relapsed/Refractory Mature B-Cell Neoplasms
NCT03664297Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edralbrutinib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) and 4 more, sponsored by Hengrui. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Recommended phase 2 dose at 28 days. Status: unknown.
02
Drugs
edralbrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03664297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664297.